MDMA hires new policy director
This article was originally published in The Gray Sheet
Executive Summary
Ben Wallfisch, who worked on legislative and regulatory healthcare issues at Patton Boggs, joins small company trade association March 18. Wallfisch will fill the vacancy created when former MDMA Executive Director Larry Holden left the association last December and was replaced by Director of Federal Affairs Mark Leahey (1"The Gray Sheet" Dec. 16, 2002, p. 8). Wallfisch also has served as a healthcare researcher at The Advisory Board Company. Separately, Shannon Scott joins MDMA as director of member services March 17, replacing Elizabeth Cholis...
You may also be interested in...
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.